As far as the therapeutic window of PARP inhibitors’ administration, the current study reveals that delaying the start of PARP inhibition to 3 h post-LPS in the current model of ALI essentially produced identical protective effects when compared to earlier administration of the inhibitor. The gene discussed is PARP1; the disease is acute respiratory distress syndrome.